• Aug 26, 2026

  $114.10-1.75%

  Comparable listed companies in Pharmaceutical Preparations fell -1.32% on average, with all six peers declining [1]. ABT fell alongside the broader sector move.

  • 1Peer group

• Aug 25, 2026

  $116.13-0.46%

  Seeking Alpha reported that Abbott gained approval of a wearable device that measures glucose and ketone levels [1]. Despite this, the stock declined slightly, moving against comparable listed companies in Pharmaceutical Preparations, which rose +1.50% on average with all six peers advancing [2].

  • 1Seeking Alpha
  • 2Peer group

• Aug 24, 2026

  $116.67+0.03%

• Aug 21, 2026

  $116.64+2.19%

  Comparable listed companies in Pharmaceutical Preparations rose +1.55% on average, with all six peers advancing [1]. ABT rose alongside the broader sector move.

  • 1Peer group

• Aug 20, 2026

  $114.14-0.25%

  Seeking Alpha reported that Abbott reached a $670 million settlement for some NEC infant formula claims [1]. Comparable listed companies in Pharmaceutical Preparations also fell -2.05% on average, with all six peers declining [2].

  • 1Seeking Alpha
  • 2Peer group

• Aug 19, 2026

  $114.43+1.55%

  Comparable listed companies in Pharmaceutical Preparations rose +4.94% on average, with all six peers advancing [1]. ABT rose alongside the broader sector move, though by less than the peer group average.

  • 1Peer group

• Aug 18, 2026

  $112.68+2.09%

  Comparable listed companies in Pharmaceutical Preparations rose +1.57% on average, with five of six peers advancing [1]. ABT rose alongside the broader sector move.

  • 1Peer group

Closing prices for ABT. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.